DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

Chao Zhang, Hong Lei Zhang, Meng Nan Han, Xue Li Yang, Chao Hong Pei, Zhi Dong Xu, Jie Du, Wei Li, Shengxi Chen

    Research output: Contribution to journalArticle

    Abstract

    Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

    Original languageEnglish (US)
    Pages (from-to)1982-1989
    Number of pages8
    JournalRSC Advances
    Volume9
    Issue number4
    DOIs
    StatePublished - Jan 1 2019

    Fingerprint

    Chemotherapy
    Cisplatin
    DNA
    Nanoparticles
    Toxicity
    Molecules
    Pharmaceutical Preparations

    ASJC Scopus subject areas

    • Chemistry(all)
    • Chemical Engineering(all)

    Cite this

    Zhang, C., Zhang, H. L., Han, M. N., Yang, X. L., Pei, C. H., Xu, Z. D., ... Chen, S. (2019). DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. RSC Advances, 9(4), 1982-1989. https://doi.org/10.1039/C8RA08735K

    DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. / Zhang, Chao; Zhang, Hong Lei; Han, Meng Nan; Yang, Xue Li; Pei, Chao Hong; Xu, Zhi Dong; Du, Jie; Li, Wei; Chen, Shengxi.

    In: RSC Advances, Vol. 9, No. 4, 01.01.2019, p. 1982-1989.

    Research output: Contribution to journalArticle

    Zhang, C, Zhang, HL, Han, MN, Yang, XL, Pei, CH, Xu, ZD, Du, J, Li, W & Chen, S 2019, 'DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy' RSC Advances, vol. 9, no. 4, pp. 1982-1989. https://doi.org/10.1039/C8RA08735K
    Zhang, Chao ; Zhang, Hong Lei ; Han, Meng Nan ; Yang, Xue Li ; Pei, Chao Hong ; Xu, Zhi Dong ; Du, Jie ; Li, Wei ; Chen, Shengxi. / DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy. In: RSC Advances. 2019 ; Vol. 9, No. 4. pp. 1982-1989.
    @article{c3bfc0c058d14870bf386dc2d9442c29,
    title = "DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy",
    abstract = "Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57{\%} at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9{\%}, 33.3 μM).",
    author = "Chao Zhang and Zhang, {Hong Lei} and Han, {Meng Nan} and Yang, {Xue Li} and Pei, {Chao Hong} and Xu, {Zhi Dong} and Jie Du and Wei Li and Shengxi Chen",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1039/C8RA08735K",
    language = "English (US)",
    volume = "9",
    pages = "1982--1989",
    journal = "RSC Advances",
    issn = "2046-2069",
    publisher = "Royal Society of Chemistry",
    number = "4",

    }

    TY - JOUR

    T1 - DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

    AU - Zhang, Chao

    AU - Zhang, Hong Lei

    AU - Han, Meng Nan

    AU - Yang, Xue Li

    AU - Pei, Chao Hong

    AU - Xu, Zhi Dong

    AU - Du, Jie

    AU - Li, Wei

    AU - Chen, Shengxi

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

    AB - Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

    UR - http://www.scopus.com/inward/record.url?scp=85060297477&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85060297477&partnerID=8YFLogxK

    U2 - 10.1039/C8RA08735K

    DO - 10.1039/C8RA08735K

    M3 - Article

    VL - 9

    SP - 1982

    EP - 1989

    JO - RSC Advances

    JF - RSC Advances

    SN - 2046-2069

    IS - 4

    ER -